A Phase 1b Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Bemarituzumab in Combination with Other Anti-Cancer Therapies in Subjects with Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression (FORTITUDE-103)

Project: Clinical Trial

Project Details

StatusNot started